Companies/US/ZYME

ZYMEWORKS INC.

Income flow

Annual
ZYME 10-K Income StatementPeriod 2025-12-31Source 10-K
Commercial Sales Milestones$66MCommercial Milestones$13MDevelopment Milestone$13MUpfront Fee$4MResearch Milestone$3MMilestone Revenue$2MMetastatic Castration Resistant Prostate Cancer$2MRecognition Of Deferred Revenue$1MBispecific Antibodies$606,670Option Exercise Fee$568,754Drug Supply For Ongoing Studies$496,560Technology Service$455,003Research Support Payments And Other Service$425,883Royalty$188,144Drug Supply$159,478Research Period Extension Fee$18,958Revenue$106M+39% Y/YCost of revenue$199M

As-filed revenue segments and annual P&L (gross, opex, tax, net). Layout inspired by SankeyArt finance diagrams.

Revenue mix

2025-12-31 · 10-K · USD
By activity
By activity$1.4B
  • Commercial Sales Milestones$867M62.0%
  • Commercial Milestones$170M12.2%
  • Development Milestone$169M12.1%
  • Upfront Fee$50M3.6%
  • Research Milestone$35M2.5%
  • Milestone Revenue$25M1.8%
  • Metastatic Castration Resistant Prostate Cancer$25M1.8%
  • Recognition Of Deferred Revenue$18M1.3%
  • Bispecific Antibodies$8M0.6%
  • Option Exercise Fee$8M0.5%
  • Drug Supply For Ongoing Studies$7M0.5%
  • Technology Service$6M0.4%
  • Research Support Payments And Other Service$6M0.4%
  • Royalty$2M0.2%
  • Drug Supply$2M0.1%
  • Research Period Extension Fee$250,0000.0%

Capital & dividends

YieldTrailing twelve-month dividends as a percent of the current share price (income yield).0.00%Trailing DPSCash dividends paid per share over the last twelve months (dividend per share, trailing).0PayoutShare of earnings paid out as dividends. Higher means more income returned; lower leaves more for reinvestment.0.0%Shares outTotal shares currently outstanding (issued and not retired).71.2MFloatShares available to trade — outstanding minus closely held (insiders, strategic holders).65.8M